Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 17;4(4):e000483. doi: 10.1136/esmoopen-2018-000483

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

2015 ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe: (1) Asian data of recently approved medications not on the WHO Model List of Essential Medicines, with an ESMO-MCBS score greater than two (2): Dominant barrier to accessibility.18 Abirat, abiraterone; Aftatin, atafinib; Axitin, axitinib; Cetux, cetuximab; CRC, colorectal cancer; Erlot, eroltinib; Enzalut, enzalutamide; Everol, everolimus; Gefit, gefitinib; Ipilim, ipilimumab; Lapat, lapatinib; MBC, metastatic breast cancer; Melan, melanoma; Panitum, panitumumab; Pazop, pazopanib; Pertuz, pertuzumab; Prost, prostate; RCC, renal cell cancer; Soraf, sorafenib; Suni, sunitinib; Vemuraf, vemurafenib.Figure reproduced with permission from Cherny et al., Annals of Oncology 2017